[1] Wu H, Li XM, Wang JR, et al.NUR77 exerts a protective effect against inflammatory bowel disease by negatively regulating the TRAF6/TLR-IL-1R signalling axis[J]. J Pathol, 2016, 238(3):457-469. [2] Cortez-Toledo O, Schnair C, Sangngern P, et al.Nur77 deletion impairs muscle growth during developmental myogenesis and muscle regeneration in mice[J]. PLoS One, 2017, 12(2):1-17. [3] Liu TY, Yang XY, Zheng LT, et al.Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death[J]. Neurochem, 2017, 140(4):589-604. [4] Wu L, Chen L.Characteristics of Nur77 and its ligands as potential anticancer compounds(Review)[J]. Mol Med Rep, 2018, 18(6):4793-4801. [5] Hou Z, Mao J, Lu Y, et al.rApoptin induces apoptosis in human breast cancer cells via phosphorylation of Nur77 and Akt[J]. Biochem Biophys Res Commun, 2018, 498(1):221-227. [6] Maddika S.Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway[J]. Cell Sci, 2005, 118(19):4485-4493. [7] Mou H, Zheng Y, Zhao P, et al.Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways[J]. Toxicol Vitr, 2011, 25(5):1027-1032. [8] Li X, Wang H, et al.Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells[J]. Eur J Pharmacol, 2019, 842:146-156. [9] Wang Q, Yu X, Li F, et al.Efficacy of celastrol combined with cisplatin in enhancing the apoptosis of U-2OS osteosarcoma cells via the mitochondrial and endoplasmic reticulum pathways of apoptosis[J]. Oncol Lett, 2019, 17(3):3305-3313. [10] Lin FZ, Wang SC, Hsi YT, et al.Celastrol induces vincristine multidrug resistance oral cancer cell apoptosis by targeting JNK1/2 signaling pathway[J]. Phytomedicine, 2019, 54:1-8. [11] Yu X, Zhou X, Fu C, et al.Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway[J]. Oncol Rep, 2015, 34(3):1129-1136. [12] Greil R, Anether G, Johrer K, et al.Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders:pathways, targets, and therapeutic tools[J]. Leukoc Biol, 2003, 74(3):311-330. [13] Los M, Wesselborg S, Schulze-Osthoff K.The role of caspases in development, immunity, and apoptotic signal transduction:lessons form knockout mice[J]. Immunity, 1999, 10(6):629-639. [14] Tait SWG, Green DR.Mitochondria and cell death:Outer membrane permeabilization and beyond[J]. Nat Rev Mol Cell Biol, 2010, 11(9):621-632. [15] Hu M, Luo Q, Alitongbieke G, et al.Celastrol-induced Nur77 interaction with TRAF2 alleviates inflammation by promoting mitochondrial ubiquitination and autophagy[J]. Mol Cell, 2017, 66(1):141-153. [16] Pei L, Castrillo A, Tontonoz P.Regulation of cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3 hui by the orphan nuclear receptor Nur77[J]. Mol Endocrinol, 2005, 20(4):786-794. [17] Burek M, Schulze-Osthoff K, Los M, et al.Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent[J]. Oncogene, 2005, 25(15):2213-2222. [18] Castro J, Ribo M, Benito A, et al.Apoptin, A versatile protein with selective antitumor activity[J]. Curr Med Chem, 2018, 25(30):3540-3559. [19] Chaabane W, Cieślar-Pobuda A, El-Gazzah M, et al.Human-gyrovirus-apoptin triggers mitochondrial death pathway-Nur77 is required for apoptosis triggering[J]. Neoplasia, 2014, 16(9):679-693. [20] Shen Ni L, Allaudin ZN bt, et al. Selective apoptosis induction in MCF-7 cell line by truncated minimal functional region of Apoptin[J]. BMC Cancer, 2013, 13:488-497. [21] Vilanova M, Castro J, Benito A, et al.A truncated apoptin protein variant selectively kills cancer cells[J]. Invest New Drugs, 2017, 35(3):260-268. [22] 李柳美, 曹雪玮, 王晓旦, 等. 商路皂苷甲(ESA)的联用可显著提高tApoptin凋亡蛋白的抗肿瘤活性[J]. 中国生物化学与分子生物学报, 2019, 35(10):1098-1107. [23] Chou TC.Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies[J]. Pharmacol Rev, 2006, 58:621-681. [24] DiMasi JA, Hansen RW, Grabowski HG. The price of innovation:new estimates of drug development costs[J]. Health Econ, 2003, 22:151-85. [25] Bozic I, Reiter JG, et al.Evolutionary dynamics of cancer in response to targeted combination therapy[J]. eLife, 2013, 2:1-15. [26] Mokhtari RB, Homayouni TS, Baluch N, et al.Combination therapy in combating cancer[J]. Oncotarget, 2017, 8(23):22-43. [27] Khdair A, Chen D, Patil Y, et al.Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance[J]. Control Release, 2010, 141:137-144. [28] DeVita VT Jr, Young RC, Canellos GP. Combination versus single agent chemotherapy:a review of the basis for selection of drug treatment of cancer[J]. Cancer, 1975, 35:98-110. [29] He D, Xu Q, Yan M, et al.The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma[J]. BMC Cancer, 2009, 9:343-351. [30] Chin K, Pang K, et al.Anti-inflammatory nutraceuticals and chronic diseases[J]. Adv Exp Med Biol, 2016, 928:97-130. [31] Cascão R, Fonseca JE, Moita LF.Celastrol:A spectrum of treatment opportunities in chronic diseases[J]. Frontiers in Medicine, 2017, 4:69-86. [32] Gan K, Xu L, Feng X, et al.Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differ- entiation and function in RANKL-induced RAW264. 7[J]. Int Immunopharmacol, 2015, 24(2):239-246. [33] Xu X, Wu Z, Xu C, et al.Observation on serum anti-double stranded DNA antibodies of tripterine in systemic lupus erythematosus of(NZBxW)F1 mice[J]. Ann Rheum Dis, 2003, 62(4):377-378. [34] Ding QH, Cheng Y, Chen WP, et al.Celastrol, an inhibitor of heat shock protein 90beta potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes[J]. Eur J Pharmacol, 2013, 708:1-7. [35] Kim Y, Kim K, Lee H, et al.Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect[J]. Eur J Pharmacol, 2009, 612:131-142. [36] Paris D, Ganey NJ, Laporte V, et al.Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease[J]. Neuroinflammation, 2010, 7:17-31. [37] Abu Bakar MH, Cheng KK, Sarmidi MR, et al.Celastrol protects against antimycin A-induced insulin resistance in human skeletal muscle cells[J]. Molecules, 2015, 20(5):8242-8269. [38] Liu J, Lee J, Salazar Hernandez MA, et al.Treatment of obesity with celastrol[J]. Cell, 2015, 161(5):999-1011. [39] Zhu F, Li C, Jin XP, et al.Celastrol may have an anti-atherosclerosis effect in a rabbit experimental carotid atherosclerosis model[J]. Int J Clin Exp Med, 2014, 7(7):1684-1691. [40] Selimoglu E.Aminoglycoside-induced ototoxicity[J]. Curr Pharm Des, 2007, 13(1):119-126. [41] Ji N, Li J, Wei Z, et al.Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro[J]. Biomed Res Int, 2015, 15:475-481. [42] Gu L, et al.Celastrol prevents atheroscle- rosis via inhibiting LOX-1 and oxidative stress[J]. PLoS One, 2013, 8(6):e65477. [43] Zhu H, Ding WJ, Wu R, et al.Synergistic anti- cancer activity by the combination of TRAIL/ APO-2L and celastrol[J]. Cancer Invest, 2010, 28:23-32. [44] Zheng L, Fu Y, Zhuang L, et al.Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo[J]. Int J Cancer, 2014, 135(7):1721-1732. [45] Zhang N, Fu JN, Chou TC.Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro:Experimental design and data analysis using the combination index method[J]. American Journal of Cancer Research, 2016, 6:97-104. [46] Soriano AF, Helfrich B, Chan DC, et al.Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines[J]. Cancer Res, 1999, 59(24):6178-6184. [47] Gupta V, Dixit NM.Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents[J]. PLoS Comput Biol, 2018, 14:1-21. [48] Wang A, Rud J, Olson CM, et al.Phosphorylation of Nur77 by the MEK-ERK-RSK cascade induces mitochondrial translocation and Apoptosis in T cells[J]. Immunol, 2009, 183:3268-3277. [49] Agostini-Dreyer A, Jetzt AE, Stires H, et al.Endogenous IGFBP-3 mediates intrinsic apoptosis through modulation of Nur77 phosphorylation and nuclear export[J]. Endocrinology, 2015, 156:4141-4151. |